These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

319 related items for PubMed ID: 16298821

  • 1. Acute tumor lysis syndrome induced by rituximab in diffuse large B-cell lymphoma.
    Jabr FI.
    Int J Hematol; 2005 Nov; 82(4):312-4. PubMed ID: 16298821
    [Abstract] [Full Text] [Related]

  • 2. Tumor lysis syndrome occurring after the administration of rituximab in lymphoproliferative disorders: high-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia.
    Yang H, Rosove MH, Figlin RA.
    Am J Hematol; 1999 Dec; 62(4):247-50. PubMed ID: 10589082
    [Abstract] [Full Text] [Related]

  • 3. Rituximab-induced tumor progression: does it really happen?
    Ozguroglu M, Turna H.
    Med Oncol; 2004 Dec; 21(2):205-6. PubMed ID: 15299193
    [Abstract] [Full Text] [Related]

  • 4. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment.
    Davis TA, Grillo-López AJ, White CA, McLaughlin P, Czuczman MS, Link BK, Maloney DG, Weaver RL, Rosenberg J, Levy R.
    J Clin Oncol; 2000 Sep; 18(17):3135-43. PubMed ID: 10963642
    [Abstract] [Full Text] [Related]

  • 5. Clinical trials of a mouse-human chimeric anti-CD20 monoclonal antibody (rituximab) for B cell non-Hodgkin's lymphoma in Japan.
    Tobinai K.
    Cancer Chemother Pharmacol; 2001 Aug; 48 Suppl 1():S85-90. PubMed ID: 11587374
    [Abstract] [Full Text] [Related]

  • 6. Diagnosis and treatment of rituximab-induced acute tumor lysis syndrome in patients with diffuse large B-cell lymphoma.
    Yang B, Lu XC, Yu RL, Chi XH, Zhang WY, Zhu HL, Yuan J, Zhao P.
    Am J Med Sci; 2012 Apr; 343(4):337-41. PubMed ID: 22270402
    [Abstract] [Full Text] [Related]

  • 7. Treatment of B-cell non-Hodgkin's lymphoma with anti CD 20 monoclonal antibody Rituximab.
    Sacchi S, Federico M, Dastoli G, Fiorani C, Vinci G, Clò V, Casolari B.
    Crit Rev Oncol Hematol; 2001 Jan; 37(1):13-25. PubMed ID: 11164715
    [Abstract] [Full Text] [Related]

  • 8. Rapid tumor lysis in a patient with B-cell chronic lymphocytic leukemia and lymphocytosis treated with an anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab).
    Jensen M, Winkler U, Manzke O, Diehl V, Engert A.
    Ann Hematol; 1998 Jan; 77(1-2):89-91. PubMed ID: 9760161
    [Abstract] [Full Text] [Related]

  • 9. [Clinical observation of Rituximab in a CD20+B non-Hodgkin's lymphoma].
    Hao LC, Zhang LZ.
    Zhonghua Er Ke Za Zhi; 2003 Aug; 41(8):627. PubMed ID: 14744396
    [No Abstract] [Full Text] [Related]

  • 10. Pathogenic study of anti-CD20 infusion-related severe refractory shock in diffuse large B-cell lymphoma.
    Gutiérrez A, Rodríguez J, Martínez J, Amezaga R, Ramos R, Galmes B, Bea MD, Ferrer J, Pons J, Sampol A, Morey M, Duran MA, Raurich J, Besalduch J.
    Leuk Lymphoma; 2006 Jan; 47(1):111-5. PubMed ID: 16321834
    [Abstract] [Full Text] [Related]

  • 11. Acute tumor lysis syndrome in large B-cell non-Hodgkin lymphoma induced by steroids and anti-CD 20.
    Abou Mourad Y, Taher A, Shamseddine A.
    Hematol J; 2003 Jan; 4(3):222-4. PubMed ID: 12764356
    [No Abstract] [Full Text] [Related]

  • 12. Rituximab in cutaneous B-cell lymphoma: a report of two cases.
    Sabroe RA, Child FJ, Woolford AJ, Spittle MF, Russell-Jones R.
    Br J Dermatol; 2000 Jul; 143(1):157-61. PubMed ID: 10886152
    [Abstract] [Full Text] [Related]

  • 13. A study of rituximab and ifosfamide, carboplatin, and etoposide chemotherapy in children with recurrent/refractory B-cell (CD20+) non-Hodgkin lymphoma and mature B-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group.
    Griffin TC, Weitzman S, Weinstein H, Chang M, Cairo M, Hutchison R, Shiramizu B, Wiley J, Woods D, Barnich M, Gross TG, Children's Oncology Group.
    Pediatr Blood Cancer; 2009 Feb; 52(2):177-81. PubMed ID: 18816698
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases.
    Chow KU, Sommerlad WD, Boehrer S, Schneider B, Seipelt G, Rummel MJ, Hoelzer D, Mitrou PS, Weidmann E.
    Haematologica; 2002 Jan; 87(1):33-43. PubMed ID: 11801463
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.